<DOC>
	<DOCNO>NCT00649584</DOCNO>
	<brief_summary>This study examine safety profile SGN-35 alone combination gemcitabine . The study test increase dos SGN-35 give weekly small group patient .</brief_summary>
	<brief_title>A Phase I Dose Escalation Study SGN-35 Alone Combination With Gemcitabine CD30-Positive Malignancies</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>Histologically confirm CD30positive hematologic malignancy . Patients HL must fail systemic chemotherapy . Patients CD30positive malignancy ( include ALCL ) must beyond first remission refractory front line chemotherapy . Patients must measurable disease least 1.5 cm document radiographic technique . Current diagnosis primary cutaneous ALCL ( systemic ALCL eligible ) . History allogeneic stem cell transplant . Patients previous treatment antiCD30 antibody .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Antigens , CD30</keyword>
	<keyword>Antibody-Drug Conjugate</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>monomethyl auristatin E</keyword>
	<keyword>Combined Modality Therapy</keyword>
	<keyword>Drug Therapy</keyword>
	<keyword>Immunotherapy</keyword>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Disease , Hodgkin</keyword>
	<keyword>Lymphoma , Large-Cell , Anaplastic</keyword>
	<keyword>Hematologic Diseases</keyword>
	<keyword>Lymphoma</keyword>
</DOC>